Estrogen receptor (ER) expression in breast cancer is associated with a more favorable prognosis and necessary for response to endocrine therapies. Traditionally, ER expression is assessed by in vitro assays on biopsied tumor tissue. However, recent advances have allowed in vivo evaluation of ER expression with 
INTRODUCTION
Breast cancer is the most common cancer in women and the 2 nd most common cause of cancer death in women in the United States, with an estimated 231,840 new diagnoses in 2015 (1) . Approximately 75% of newly diagnosed patients have estrogen receptor (ER) expressing breast tumors, which are associated with a more favorable prognosis (2) . ER expression in breast cancer is traditionally assessed by in vitro assays on biopsied tissue using qualitative and/or semi-quantitative immunohistochemical staining (3) . A tumor's ER status predicts likelihood of response to ER-targeted therapy, also known as endocrine or hormone therapy (4) . While absence of ER by in vitro assay indicates low likelihood of response and is associated with a worse prognosis, the presence of ER by immunohistochemistry does not necessarily guarantee response to endocrine therapy (5) . Nevertheless, it is important to identify ER-positive patients with recurrent and metastatic disease, whom may respond to hormone therapy and potentially avoid toxic side effects of chemotherapy (6) .
For patients with advanced or metastatic ER-positive disease, the advent of positron emission tomography (PET) and PET combined with computed tomography (PET/CT) has made it possible to evaluate ER expression in all metastatic lesions without multiple biopsies. Used with 18 F-fluorodeoxyglucose ( 18 F-FDG) to detect increased glucose metabolism, PET imaging possesses widespread oncologic applications (7) . In breast cancer, 18 F-FDG-PET/CT is recommended primarily for locally advanced or metastatic disease when standard staging studies are equivocal or suspicious (8) .
Other radiotracers have subsequently been developed to better characterize tumor biology, including has the potential to assess heterogeneity in ER expression and identify sites that have lost ER expression or functionality. 18 F-FES-PET has been evaluated in numerous breast cancer clinical studies as a promising method for quantifying in vivo ER expression, predicting response to hormone therapy, and evaluating effective ER blockade (Supplemental Table 1 ). This review by on November 7, 2017 . For personal use only. jnm.snmjournals.org Downloaded from 4 providers background for practitioners by highlighting the biology and pharmacology of 18 F-FES, reviewing current clinical experience with 18 F-FES, and summarizing its potential applications.
18

F-FES STRUCTURE, SYNTHESIS, PHARMACOKINETICS, AND SAFETY
Early efforts to develop an ER targeting radiotracer involved labeling steroid and nonsteroid compounds with iodine and bromine (9) . However, the subsequent advent of PET imaging and 18 F -a small halogen that displayed uptake in target tissues, elimination in non-target tissue, substitution at several positions in various estrogen analogs, and a half-life long enough to allow for multistep synthesis (10, 11 (14) . Its non-SHBG-bound metabolites, comprised of glucoronide and sulfate conjugation products (11) , are secreted in bile, resorbed via enterohepatic circulation, and renally excreted.
The rate of decline in total liver activity is similar to the rate of increase in total bladder activity, In this same study, F-FES uptake was inversely associated with plasma SHBG levels but not with testosterone levels, patient age or disease stage at time of imaging -discrepancies suggesting that although a certain amount of binding to SHBG may be necessary to protect F-FES from metabolism, protein-bound F-FES SUV < 1.5 responded to endocrine therapy by demonstrating disease stabilization (Supplemental Fig. 2 
) (26).
Applying a SUV threshold of 1.5 to these data, van Kruchten et al. studied the relationship between baseline 18 F-FES-PET and response to low-dose oral estradiol as salvage therapy (28) . It is thought that long-term anti-estrogen therapy may induce hypersensitivity to estrogens, whereby estrogen exposure activates apoptosis rather than growth pathways (29) . In this scenario, the presence of ER, which could be measured by 18 
F-FES-PET, is necessary to
by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from 8 induce these apoptotic pathways. The threshold SUV of 1.5 demonstrated a PPV of 60% and NPV of 80% for response to low-dose estradiol (28) .
An alternative approach to predicting response utilizes 18 F-FDG-PET imaging, which has been established as a predictive biomarker in cancers such as lymphoma (30) . In breast cancer, a clinical "flare" can occasionally be seen with therapeutic agents possessing ER agonist properties, where initial symptom exacerbation upon therapy initiation predicts subsequent response (31) . Studies have shown that 18 F-FDG-PET can also detect subclinical "metabolic flares" in patients who subsequently respond to therapy (23, 24) . Comparison of F-FES-PET is able to predict response for various endocrine therapies, prior to any exposure to therapy, directing patients without ER expression away from likely unbeneficial endocrine treatments. In addition, the increasing use of therapeutic strategies combining endocrine and other targeted therapy increases the need to determine ER expression and suitability for combined treatment. One potential framework for combining both approaches would be to first select patients whose tumors express ER by using 18 F-FES to confirm target expression, followed by serial 18 
F-FDG-PET or other standard imaging
to predict responsiveness by assessing the pharmacodynamic response to a specific types of therapy (Supplemental Fig. 3) (32) . Table 4 ) (17, 21, 33) . Among multiple metastatic sites in individual patients, There was also a small number of patients that demonstrated highly discordant (47, 48) . Given the substantial management and prognostic differences between the two entities, 18 F-FES-PET can potentially play a role in risk stratification of indeterminate uterine masses.
ABILITY OF
Epithelial Ovarian Cancer
Up to 70% of epithelial ovarian cancers express ER at baseline (51), and 
POTENTIAL CLINICAL USES
As described in this review, Nonetheless, because it is highly specific for ER-expressing breast cancers, 18 F-FES could be a beneficial adjunct that expands the focus in radionuclide breast cancer beyond F-FDG-PET, particularly in less differentiated cancers (e.g., invasive lobular carcinoma) that tend to be less 18 F-FDG-avid, and also help with false-positive uptake due to inflammation, healing, and other know non-cancer causes of FDG uptake (7, 21, 34, 65) .
Knowledge of 18 F-FES uptake might also obviate the need for invasive biopsy, particularly in the metastatic setting, potentially improving the cost-effectiveness of metastatic disease workup (66) .
Finally, our advancing knowledge about predisposing factors for specific types of breast cancer could one day lead to a scenario where patients prospectively identified as high-risk for ERexpressing cancers might benefit from adjunct screening with 18 F-FES-PET.
Predicting Response to Endocrine Therapy
Consistent with growing emphasis on precision medicine and individualized care, as well as evidence that In the clinic, PET ER imaging would have its greatest impact in patients with metastatic breast cancer, where it is not practical to biopsy all sites of disease. As such, clinicians often base their choice of endocrine therapy on ER status in the primary tumor and not in the metastatic sites. However, studies suggest that up to 30% of patients may lose ER expression at one or more sites of disease after undergoing several lines of endocrine therapy (16, 28, 36, 38) . Based upon these considerations, the most immediately compelling clinical use of 
